On Jan. 1, 2014, six elected Board of Trustees positions will become vacant. Elections to fill those positions and decide on proposed changes to the Code of Ethics will take place by hybrid (mail and online) ballot after the Nov. 17 annual business meeting in New Orleans.
In accordance with Academy bylaws, notice is hereby given of the following nominations for officers to the Academy, made by the Board of Trustees in June. The nominees for Chair and Vice Chair of the Council were nominated by the Council during their April 2013 meeting.
President-Elect: Russell N. Van Gelder, MD, PhD - Candidate Statement
Senior Secretary for Ophthalmic Practice: Robert E. Wiggins Jr., MD, MHA - Candidate Statement
Secretary for Annual Meeting: Jonathan B. Rubenstein, MD - Candidate Statement
Trustee-at-Large: Jane C. Edmond, MD - Candidate Statement
Council Chair: Ann A. Warn, MD, MBA - Candidate Statement
Council Vice Chair: Mathew W. MacCumber, MD, PhD - Candidate Statement
Any questions relating to the nomination process or election process may be e-mailed to the Nominating Committee at firstname.lastname@example.org.
During the June 2013 Board of Trustees meeting, Paul B. Ginsburg, PhD was re-appointed for another term as Public Trustee and will begin his new term on January 1.
The Board of Trustees recommends the following proposed change to the Academy Code of Ethics. New language is underlined, and deleted words and phrases are indicated by
strike through. Only the affected portions of the current documents are printed here.
Code of Ethics:
B. RULES OF ETHICS
3. Research and Innovation
in Clinical Practice.Research and innovation in clinical practice shall be approved by appropriate review mechanisms to protect patients from being subjected to or potentially affected by inappropriate, ill-considered, or fraudulent basic science or patient-oriented research. Basic science and clinical Rresearch and innovations in clinical practice are conducted to develop adequate information on which to base prognostic or therapeutic decisions or to determine etiology or pathogenesis, in circumstances in which insufficient information exists. Appropriate informed consent for research and innovative procedures must recognize their special nature and ramifications. In emerging areas of ophthalmic treatment where recognized guidelines do not exist, the ophthalmologist should exercise careful judgment and take appropriate precautions to safeguard patient welfare.